Abstract Designing novel molecules with desired bioactivity remains a fundamental challenge in drug discovery. Most molecular design methods follow target-based drug discovery paradigms that rely on well-defined drug targets, thereby limiting their applicability to diseases lacking known targets or reference compounds. Here we introduce Morphology-Guided Molecule Generation (MGMG), a phenotypic drug discovery–oriented approach that integrates cellular morphological profiles from compound treatments with molecular textual descriptions without requiring molecular target information. Cell morphology offers the guidance on desired bioactivity-relevant phenotypic effects, while textual descriptions provide direct and interpretable cues about molecular structure. Leveraging complementary structural and bioactivity context, MGMG significantly enhances molecule generation performance, especially in scenarios where textual descriptions are under-informative or morphological signals are weak. MGMG can also be applied to genetic perturbations, enabling activator design from gene overexpression morphology without requiring knowledge of reference compound structure. In addition, in silico docking demonstrates that MGMG-generated molecules, despite lacking target information, exhibit binding affinities comparable to reference compounds, preserving key interactions while introducing structural diversity. Overall, MGMG jointly utilizes morphological and textual description inputs to guide molecule generation, enabling diverse, bioactivity-aware compound design in a target-agnostic fashion.
Tang et al. (Thu,) studied this question.